Core Insights - Wall Street analysts expect Becton Dickinson (BDX) to report quarterly earnings of $2.82 per share, reflecting a year-over-year decline of 17.8% and revenues of $5.15 billion, down 0.4% from the previous year [1] Earnings Estimates - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong correlation between earnings estimate revisions and short-term stock performance [2] Revenue Projections - Analysts project 'Revenues- BD Interventional' to reach $1.30 billion, indicating a year-over-year increase of 3.6% [4] - 'Revenues- BD Interventional- Surgery' is expected to be $407.30 million, up 3.1% from the prior year [4] - 'Revenues- BD Interventional- Peripheral Intervention' is forecasted at $487.99 million, reflecting a 3.2% increase year over year [4] - 'Revenues- BD Interventional- Urology and Critical Care' is estimated at $406.86 million, showing a 4.6% increase [5] - 'Revenues- BD Medical- Medication Management Solutions- International' is projected to be $141.04 million, down 0.7% from the previous year [5] - 'Revenues- BD Life Sciences- Biosciences- International' is expected to be $205.77 million, down 1.1% year over year [6] - 'Revenues- BD Interventional- Peripheral Intervention- United States' is estimated at $257.71 million, up 1.9% from the prior year [6] - 'Revenues- BD Interventional- Urology and Critical Care- United States' is projected at $317.53 million, indicating a 3.8% increase [7] - 'Revenues- BD Interventional- United States' is expected to be $885.03 million, reflecting a 2.8% increase [7] - 'Revenues- BD Interventional- Surgery- International' is forecasted at $98.59 million, up 7.2% from the previous year [8] - 'Revenues- BD Interventional- Peripheral Intervention- International' is estimated at $229.03 million, indicating a 4.1% increase [8] - 'Revenues- BD Interventional- Urology and Critical Care- International' is projected at $88.55 million, reflecting a 6.7% increase year over year [9] Stock Performance - Over the past month, Becton Dickinson shares have returned +0.6%, compared to the Zacks S&P 500 composite's +0.9% change, with a Zacks Rank 4 (Sell) indicating potential underperformance in the near future [10]

Becton, Dickinson and Company (NYSE:BDX) is included among the Dividend Growth Stocks: 25 Aristocrats. Piper Sandler Highlights Upcoming Segment Transition at Becton Dickinson (BDX) On January 28, Piper Sandler analyst Jason Bednar lifted Becton, Dickinson and Company (NYSE:BDX)’s price recommendation to $205 from $190. The analyst maintained a Neutral rating. The firm pointed to changes in how BD reports its business units starting in Q1 2026 and said it is updating its financial model to align with the ...

Core Insights - Becton, Dickinson and Company (BDX) has successfully completed a joint feasibility study on recycling polystyrene Petri dishes into high-quality manufacturing feedstock, in collaboration with Envetec Sustainable Technologies [1][8] - The pilot study indicates that several polymers, including polystyrene, can be reintroduced into the manufacturing supply chain after effective disinfection and processing [1][4] Company Initiatives - The pilot project is part of BD's Sustainable Medical Technologies Institute and aims to develop circular economy solutions for single-use plastic medical devices, addressing long-term environmental concerns [2][4] - The initiative supports BD's strategic objective of reducing reliance on virgin plastics and lowering waste-management costs over time, positioning the company as an innovator in sustainable healthcare solutions [5][11] Market Performance - Following the announcement, BDX shares gained 1.2%, with a 13.8% increase over the past six months, compared to the industry's 15.7% growth and the S&P 500's 12.3% rise [3] Technological Advancements - The pilot utilized Envetec's GENERATIONS technology, which disinfects waste into clean, recyclable polymer flakes, demonstrating that recycled materials can meet performance standards for new products [9][10] Industry Trends - The sustainable laboratory plasticware market is projected to reach $970.97 million by 2026, with a CAGR of 19.2% through 2035, driven by increasing demand for recyclable and biodegradable products [12]

Core Insights - The article discusses the 25 best dividend aristocrat stocks, which are companies that have consistently raised their dividends for at least 25 years, appealing to investors due to their reliability in dividend growth [1] Group 1: Dividend Aristocrats Overview - Dividend aristocrats are typically mature companies with stable earnings, and management prioritizes dividend increases as a core responsibility [2] - Despite their reputation, dividend aristocrats can still reduce dividends, as evidenced by Walgreens Boots Alliance's significant cut in early 2024, highlighting that historical performance does not guarantee future safety [3] Group 2: Importance of Dividends - Research from S&P Dow Jones Indices indicates that dividends have contributed approximately 31% to the total return of the S&P 500 since 1926, with capital appreciation accounting for 69% [5] - The S&P 500 Dividend Aristocrats have historically provided higher returns with lower volatility compared to the broader S&P 500, leading to stronger risk-adjusted returns [6] Group 3: Methodology for Stock Selection - The article's methodology involved scanning a list of Dividend Aristocrats to identify companies with the strongest dividend growth rates over the past five years, resulting in a selection of 25 companies ranked by their growth rates [8] Group 4: Company Highlights - **Eversource Energy (NYSE:ES)**: - 5-Year Average Dividend Growth Rate: 5.81% - The company serves approximately 4.6 million customers and is focused on regulated utility operations, with plans to invest about $24.2 billion from 2025 to 2029 for infrastructure modernization [10][12] - Recently raised its quarterly dividend by 4.7% to $0.7875 per share, marking 26 consecutive years of dividend growth [13] - **Becton, Dickinson and Company (NYSE:BDX)**: - 5-Year Average Dividend Growth Rate: 5.97% - Announced a $110 million investment to expand production of prefillable syringes, expected to create around 120 new jobs [15][16] - Remains a leading medical technology company focused on healthcare advancements [17] - **General Dynamics Corporation (NYSE:GD)**: - 5-Year Average Dividend Growth Rate: 6.40% - Reported fourth-quarter results exceeding estimates, driven by strength in combat and marine systems, although full-year profit outlook was below expectations [19][22] - The company is experiencing strong demand across its business segments, particularly in defense, amid ongoing geopolitical tensions [21]

Core Insights - BD reported record revenue of $21.8 billion for fiscal 2025, reflecting a 7.7% growth on an adjusted foreign exchange-neutral basis and 2.9% organic growth, with management highlighting solid performance across key platforms in a dynamic market environment [1][5] - The company described fiscal 2025 as the culmination of its BD 2025 strategy and the beginning of a new growth phase, emphasizing the most prolific growth period in its 128-year history with over $5.4 billion in organic revenue added [1][7] - BD plans to close the combination of its Biosciences and Diagnostic Solutions business with Waters Corp. on February 9, allocating at least half of the expected $4 billion in cash proceeds to share repurchases and the remainder to debt repayment [4][13] Financial Performance - BD achieved a record adjusted operating margin of 25% and reported a 9.6% growth in adjusted diluted EPS, alongside returning $2.2 billion to shareholders, marking its 54th consecutive dividend increase [5][6][10] - The company launched over 125 new products and generated $1.3 billion through more than 20 tuck-in acquisitions while divesting non-strategic assets [8][10] Annual Meeting Outcomes - Shareholders approved all four proposals at the annual meeting, including the election of directors and the ratification of Ernst & Young as the independent auditor for fiscal 2026, with significant support for each proposal [3][15] - The advisory "Say on Pay" vote on executive compensation received approximately 91% support, and the amendment to the 2004 Equity Compensation Plan received 96% support [15] Strategic Initiatives - BD's management highlighted the BD Excellence operating system's contribution to profit and loss leverage, achieving record service levels and consumables quality while navigating macro challenges [6][10] - The company outlined an enhanced capital allocation framework focused on share repurchases, reliable and increasing dividends, and targeted high-growth market acquisitions [14]

Group 1 - The core point of the article is that Beckton Dickinson has obtained a patent for a component designed to prevent the residual extraction of particles [1] - The patent is titled "Magnetic Component for Preventing Residual Extraction of Particles" and was granted under the announcement number CN114585444B [1] - The application date for the patent was December 2020 [1]

Core Viewpoint - The collaboration between BD and Envetec has successfully demonstrated a feasible method for recycling polystyrene Petri dishes and other plastics used in healthcare, paving the way for sustainable practices in the industry [1][4]. Group 1: Recycling Feasibility - A joint feasibility study has shown that polystyrene, polyester (PET), polypropylene, and polyethylene can be recycled into high-quality manufacturing feedstock after proper disinfection and processing [2][3]. - Envetec's GENERATIONS® technology effectively converts regulated waste into recyclable polymer flakes through a low-energy chemical disinfection process, enabling the transformation of medical waste into new products [3][8]. Group 2: Industry Impact - The pilot project represents a significant step towards creating sustainable solutions for healthcare supply chains, allowing for the recovery and recycling of various plastic products [4][5]. - BD emphasizes the importance of single-use devices made from high-quality plastics in healthcare while acknowledging their environmental impact, indicating a commitment to circular economy solutions for healthcare consumables [5][6]. Group 3: Future Opportunities - Both BD and Envetec see potential for expanding the pilot project to reduce reliance on virgin plastics and maintain high-value polymers in circulation [4][6]. - Envetec is actively developing sustainable circular pathways for treated laboratory plastics, aiming to convert clean flakes into recycled pellets and new plastic products [6][8].

Core Points - BD (Becton, Dickinson and Company) has declared a quarterly dividend of $1.05 per common share, with an annual dividend rate of $4.20 per share, payable on March 31, 2026 [1] - The company has repurchased $250 million in BD stock in fiscal 2026 and has authorized the repurchase of up to 10 million additional shares [2] - BD is a leading global medical technology company focused on improving medical discovery, diagnostics, and care delivery, with over 70,000 employees [3]

Financial Data and Key Metrics Changes - In FY 2025, the company achieved record revenue of $21.8 billion, representing a growth of 7.7% adjusted for foreign exchange and 2.9% organic growth [4] - Adjusted gross margin increased by 140 basis points, contributing to an 80 basis points expansion in adjusted operating margin, reaching a record 25% [5][8] - Adjusted diluted EPS grew by 9.6%, inclusive of tariffs, while the company returned $2.2 billion to shareholders, including a $1 billion share buyback [5] Business Line Data and Key Metrics Changes - The new BD delivered organic revenue growth of 3.9%, with solid growth across key platforms [4] - The company launched over 125 new products and added $1.3 billion through more than 20 accretive high-growth tuck-in acquisitions [6] Market Data and Key Metrics Changes - The company navigated a dynamic market environment, including changes in research spending, vaccine utilization, tariffs, and ongoing geopolitical uncertainty [8] - The agreement to combine the Biosciences and Diagnostic Solutions business with Waters Corp is expected to create a life science and diagnostics leader, enhancing growth opportunities [9] Company Strategy and Development Direction - The company is transitioning to a new growth strategy called "Excellence Unleashed," focusing on three strategic priorities: compete, innovate, and deliver [10] - The strategy aims to enhance customer experience, leverage AI and robotics for innovation, and ensure operational excellence for consistent cash flow growth [10][11] Management's Comments on Operating Environment and Future Outlook - Management highlighted the successful culmination of the BD 2025 strategy, marking the most prolific growth period in the company's history [6] - The company expressed confidence in its ability to maximize shareholder value through strategic capital allocation and a focus on high-growth markets [9] Other Important Information - The company announced its 54th consecutive year of dividend increases, reinforcing its commitment to a reliable dividend policy [5] - The transaction with Waters Corp is expected to close on February 9, subject to customary closing conditions [9] Q&A Session Summary - No questions were received during the Q&A session, and the meeting concluded without any inquiries from shareholders [14]

Financial Data and Key Metrics Changes - In FY 2025, the company achieved record revenue of $21.8 billion, representing a growth of 7.7% adjusted for foreign exchange and 2.9% organic growth [4] - Adjusted gross margin increased by 140 basis points, contributing to an 80 basis points expansion in adjusted operating margin, resulting in a record 25% adjusted operating margin [5][7] - Adjusted diluted EPS grew by 9.6%, inclusive of tariffs, while the company returned $2.2 billion to shareholders, including a $1 billion share buyback [5] Business Line Data and Key Metrics Changes - New BD delivered organic revenue growth of 3.9%, with solid growth across key platforms [4] - The company launched over 125 new products and added $1.3 billion through more than 20 accretive high-growth tuck-in acquisitions [6] Market Data and Key Metrics Changes - The company navigated a dynamic market environment, including changes in research spending, vaccine utilization, tariffs, and ongoing geopolitical uncertainty [7] - The agreement to combine the Biosciences and Diagnostic Solutions business with Waters Corp is expected to create a life science and diagnostics leader, enhancing growth opportunities [8] Company Strategy and Development Direction - The company is transitioning to a new growth strategy called "Excellence Unleashed," focusing on three strategic priorities: compete, innovate, and deliver [9] - The capital allocation framework prioritizes share repurchases, reliable and increasing dividends, and focused tuck-in M&A in high-growth markets [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute on the new growth strategy and emphasized the importance of operational excellence for reinvestment in commercial and innovation capabilities [9][10] - The company aims to maximize its platforms for faster long-term growth, building on the advancements made over the last five years [10] Other Important Information - The company announced its 54th consecutive year of dividend increases, reflecting the consistency and reliability of its dividend policy [5] - The transaction with Waters Corp is expected to close on February 9, subject to customary closing conditions [8] Q&A Session Summary Question: Were there any questions from shareholders? - There were no questions received during the Q&A session [14]